ENFN vs. ZETA, QTWO, ASAN, KC, FRSH, BOX, VRNS, WK, SAIC, and TENB
Should you be buying Enfusion stock or one of its competitors? The main competitors of Enfusion include Zeta Global (ZETA), Q2 (QTWO), Asana (ASAN), Kingsoft Cloud (KC), Freshworks (FRSH), BOX (BOX), Varonis Systems (VRNS), Workiva (WK), Science Applications International (SAIC), and Tenable (TENB). These companies are all part of the "computer software" industry.
Enfusion vs.
Enfusion (NYSE:ENFN) and Zeta Global (NYSE:ZETA) are both computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.
Zeta Global received 78 more outperform votes than Enfusion when rated by MarketBeat users. Likewise, 67.69% of users gave Zeta Global an outperform vote while only 19.61% of users gave Enfusion an outperform vote.
Enfusion has higher earnings, but lower revenue than Zeta Global. Zeta Global is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Enfusion currently has a consensus price target of $10.50, suggesting a potential downside of 8.66%. Zeta Global has a consensus price target of $37.43, suggesting a potential upside of 80.72%. Given Zeta Global's stronger consensus rating and higher probable upside, analysts plainly believe Zeta Global is more favorable than Enfusion.
In the previous week, Zeta Global had 10 more articles in the media than Enfusion. MarketBeat recorded 12 mentions for Zeta Global and 2 mentions for Enfusion. Zeta Global's average media sentiment score of 0.52 beat Enfusion's score of 0.49 indicating that Zeta Global is being referred to more favorably in the news media.
Enfusion has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Zeta Global has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.
Enfusion has a net margin of 1.70% compared to Zeta Global's net margin of -13.35%. Enfusion's return on equity of 6.67% beat Zeta Global's return on equity.
81.1% of Enfusion shares are owned by institutional investors. Comparatively, 87.8% of Zeta Global shares are owned by institutional investors. 36.4% of Enfusion shares are owned by insiders. Comparatively, 25.5% of Zeta Global shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Zeta Global beats Enfusion on 11 of the 19 factors compared between the two stocks.
Get Enfusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENFN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Enfusion Competitors List
Related Companies and Tools
This page (NYSE:ENFN) was last updated on 2/22/2025 by MarketBeat.com Staff